The annual OnCon Icon Awards recognize the world’s leading COOs as voted for by their peers. Among this year’s winners is New York resident Nicolas Fauchoux, the chief operating officer of the international research organization Biotrial. OnConferences, which connects individuals with top global executives and other professionals worldwide, oversees the awards.
The 2024 OnCon Icon Awards have honored Fauchoux as a Top 50 COO. The York City Metropolitan Area-based executive took home his award on April 23rd.
Biotrial is a global provider of analytical, clinical, and non-clinical research. The organization performs hundreds of annual studies for the international biotechnology and pharmaceutical industries.
Biotrial COO Nicolas Fauchoux
Fauchoux first joined Biotrial over two decades ago as a medical doctor. After holding numerous key positions, including leading its clinical pharmacology unit for almost ten years, he was appointed the organization’s global chief operating officer and chief medical officer in 2015.
Following his appointment, he relocated to Manhattan to oversee Biotrial’s newly opened first U.S. facility in Newark, New Jersey. Since then, he has guided Biotrial and its team to new levels of international success.
Founded in France in 1989, Biotrial continues to expand its operations in the U.S. and worldwide, with rapid growth. The company is dedicated to supporting innovative pharmaceuticals and biotechs throughout their drug development process, aiming to expedite the delivery of effective cures to patients.
New Success on U.S. Soil
Under the guidance of its COO and a team of seasoned technicians, Biotrial’s New Jersey-based team has successfully conducted numerous phase 1 studies on U.S. soil. This marks a significant step in their objective to expand in the U.S. and build on their core expertise.
In Neuroscience, Biotrial offers extensive expertise and translational solutions that seamlessly integrate preclinical and clinical development.
With over 35 years of experience in oncology trial management, Biotrial works closely with Key Opinion Leaders to ensure its trials are designed and conducted to the highest standards. Pioneering new patient-centered approaches and innovative solutions makes Biotrial a preferred partner in early-stage oncology development.
Biotrial remains wholly committed to investing in collaboration, determination, and state-of-the-art technology to achieve groundbreaking results in both the U.S. and France. The company remains focused on discovering solutions, reaching new goals, and delivering excellence at every turn.
Alongside its headquarters in Rennes, France, and its U.S. facility in Newark, New Jersey, Biotrial has additional locations in London, England, and Quebec, Canada. For more information, visit Biotrial.com.
Published By: Aize Perez
